News
Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation
GlaxoSmithKline plc announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Tafinlar® (dabrafenib) for treatment of patients with...
Production & Manufacturing
Bayer HealthCare launches oncology treatment Xofigo in UK
Bayer HealthCare has launched Xofigo (radium - 223 dichloride) solution for injection in the UK to treat adults with castration-resistant prostate cancer, symptomatic bone...
Press Releases
Adocia strengthens its diabetic foot ulcer patent portfolio
Adocia, a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic molecules, in particular proteins and oncologic drugs, announces today...
Industry Reports
RBI seeks clarity on FII investment in pharmaceutical sector
The Reserve Bank of India (RBI) has sought clarity on whether foreign portfolio investments can be allowed in existing companies without government approval, putting...
Press Releases
TxCell to present an innovative, personalized cell-based immunotherapy approach at Biotech Showcase™ 2014, San Francisco, USA
TxCell SA, a clinical stage biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces...
Press Releases
Adocia launches phase IIa clinical trial for its ultra-fast acting formulation of analog insulin
Adocia , a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, in particular proteins and oncologic treatments, launches...
Press Releases
Domain Therapeutics, Universite de Montreal, IRICoR and McGill University sign new licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology
Domain Therapeutics, a France-based biopharmaceutical company that specializes in the research and development of new drug candidates that target G-protein coupled receptors (GPCRs), is...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read